ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life – Karim Fizazi

Karim Fizazi and Alicia Morgans discuss a follow-up on the quality of life parameters evaluated in the ARAMIS trial. Darolutamide was also associated with benefits with regard to all secondary end points, including overall survival, time to pain progression, time to cytotoxic chemotherapy, and time to a symptomatic skeletal-related event. The incidence of adverse events that occurred or…

Read the full article here

Related Articles